Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...

Scientists at the Institute for Systems Biology (ISB) have uncovered key insights into how T cells—the body's frontline ...

Researchers at the (Belgium) have uncovered a previously unknown mechanism that regulates the immune response against parasites.

Prolonged illnesses, such as cancer and persistent infections, can fatigue the immune system, causing its frontline defenders ...

That's because antibodies made in response to the vaccine can still offer some protection. There are, however, things that do affect your immune system. Medications like chemotherapy or infections ...